Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder what negative articles and downgrades will be published tomorrow?
I wonder how much of today's negative info will be repeated tomorrow?
Noticed that Barron's and Benzinga likes to repeat the same negative bullchit five times a day...they must be short or work for/with shorts.
Great, a bidding war!!! LOL
I predict that GM will either outright acquire Nikola or buy 51%.
Good chit. All companies on the market are garbage. Days of going long are long gone. Lol
The markets have become an international casino!!!
The system is designed to protect and benefit short sellers.
Elon put it best..."SEC"
"Shortseller Enrichment Commission"
Anyone with a voice in media, whether print or television has the power to make a stock drop because they have followers; these same voices are short sellers.
Wedbush lost a lot of money and is now trying to recoup by going short and calling for a $15 price target. Obviously Wedbush has done its math and needs this to drop to $15 in order to recoup its loses. LOL
The lawsuits won't hold up. These "ambulance chasers" are usually looking for investors who've lost $50k minimum; and in the investing world the cliche is, "you only lose if you sell". So anyone who has sold for a loss based on a short sellers tactics, it's their own fault. Additionally, another reason the "lawsuit(s)" won't hold is because once the stock price recovers, that's evidence that whoever sold should have held, as the price recovered making ones "loss" a mute point thus going back to the cliche, "you only lose if you sell".
It's not even for sure that the DOJ or SEC are investigating NKLA as no party has confirmed nor denied it, but if they are being investigated and the investigation comes back clear, you will see NKLA quickly hit the high of the day when the GM partnership was announced...$55
MRNA must be the real deal, because apparently the Chinese tried to hack their data to win the COVID race...
https://in.reuters.com/article/us-health-coronavirus-moderna-cyber/chinese-backed-hackers-targeted-covid-19-vaccine-firm-moderna-idINKCN24V38M
It's all coming together; just within the last few hours...
Vaccine works in primates...
Moderna pitches $50 to $60 price per course...
Moderna in secret discussions with numerous governments and government entities....
...THEY HAVE THE VACCINE!!!
News out.
https://www.reuters.com/article/us-health-coronavirus-vaccines-pricing-e/exclusive-vaccine-alliance-eyes-range-of-prices-for-covid-shots-says-40-would-be-maximum-idUSKCN24S2AI
The Vaccine Alliance says $40 should be the maximum price per dose.
Pfizer will charge $19.50
Wonder what Moderna will charge? At 1 billion doses per year by 2021, that's some serious income, and that's just from 1 vaccine out of many in their pipeline.
Good luck all invested.
30,000 volunteers is a huge feat. It will be hard for other pharm companies to get 30,000 volunteers, fortunately MRNA already has theirs.
Moderna issues a statement about the suit, and the patent doesn't affect any vaccines Moderna plans to commercialize. Especially the mRNA-1273.
http://ih.advfn.com/stock-market/NASDAQ/moderna-MRNA/stock-news/82923692/statement-from-moderna-on-patent-trial-and-appeal
Back to $90's we go!
Tug of war.
Carpe diem.
Clay Trader and his crew too. They are short sellers. Burn!!!
Located in both. Headquarters in PA, and I guess labs in San Diego.
https://www.yahoo.com/news/volunteers-sign-potential-covid-19-061333968.html
https://1daysooner.org/
San Diego is synonymous with Inovio; Lol
Pertaining to Phase 3, INovio told ABC News...
"And a spokesperson for Inovio told ABC News that the company will not be testing its vaccine abroad, as "the infection rates in the U.S. are currently high and so we will be able to assess the efficacy of the vaccine in subjects in the U.S.""
Finding participants abroad will be difficult as the numbers are decreasing, but in the US the numbers are rising. INO on the smart path. Focus on US, create the vaccine for US first.
I'm no medial expert, but I read it, and it looks promising with the mentioning of the T-cells and neutralizing data. Peer review with human data on the same grounds takes this to double on 200 million volume.
Yes, it's the same woman; based on the following post. She is making her media rounds.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156694384
INO might wind up being the winner.
After mentioning Pennsylvania hospital, can the woman (trial participant) in the ABC video be talking about Inovio?
https://www.yahoo.com/gma/coronavirus-vaccine-developers-launch-phase-3-studies-us-181300659.html
Now I understand why Moderna received the most money from the government ($483 million), and why its stock never tanks. It's because Dr. Fauci is working with Moderna; he's in charge of their trial. Talk about a conflict of interest.
https://finance.yahoo.com/news/moderna-executives-cashing-covid-19-021949146.html
https://news.yahoo.com/covid-19-vaccines-enter-stage-193845818.html
Since Regeneron already has a relationship with Inovio, they might as well buy Inovio out if they want to get into the COVID race.
REGN is trading at $622; do a 1 for 1 and it's a deal. Lol
I'll see you (hear from you) on Monday, and Tuesday and so.
These so-called analysts don't do their due diligence, all they do is speculate. Cantor Fitzgerald, who's calling for a price target of $45 clearly stated that they've done their DD and thus their $45 target. These other "analyst" don't have a clue.
https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Inovio+Pharmaceuticals+%28INO%29+PT+Raised+to+%2445+at+Cantor+Fitzgerald/17051045.html
All these penny stock analyst such as Maxim, Piper Sandler, Roth Capital, etc., they are followers; they go with the flow; they know nothing.
When the big names like JP Morgan, Bank of America, Goldman Sachs, etc., provides an analysis, then it's time to listen, cause they have the clients with the big money; these other 2nd rate guys aforementioned are simply fake voices whom probably work with/for short sellers.
If these same crooks have a price target of $8, and $11, well the current price is $21+, they should sell their stake or cover (if they even have any) and move on, because their measly price targets of $8 and $11 was hit 2 and 3 fold.
They are nothing more than idiots with no clients other than short sellers.
Thanks for sharing. Kate seems pretty confident in the data. All we need is the FDA to feel the same way :)
INO is at the forefront. Once peer review is published the two faced analysts will reappear with buy ratings.
Don't know if Inovio would consider selling to a larger firm but I wouldn't rule it out.
I know, I replied to Spot Off. LOL
The New England Journal of Medicine is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journals as well as the oldest continuously published one.
I hope INO is aiming for The New England Journal of Medicine. I good peer review from there will put this in the $40 to $50 range where it should be if it weren't for fake analysis, fake downgrades and weak hands.
Thanks for sharing. I wonder why none of this ever hits the wire...only negative info hits the wires. It wouldn't surprise me if certain media outlets are also short sellers like Marketwatch.
What's your point. The stock didn't tank on that particular news which happened on June 25th, it tanked on the positive data results yesterday and carried over today.
Be careful, it might go to $7.5 after you buy it - for a 50% loss. These shorts and analyst are powerful. They've successfully made positive phase 1 data look like a negative.
Agree, it doesn't make sense.
More shorts coming in, not to mention panic sellers. Shorts aren't covering otherwise we'd be going up. The tree is being shaken to the root. LOL
Don't invest money that you can't and/or not willing to lose. You should know that cliche by now. It's the M-O of the market.
This will be back at $30 by the end of the month. I'm in no hurry.
All these analyst are bandwagon riders. Soon these same analyst will be giving INO upgrades.
I'm in at $30 & $28 and I'm confident this will hit at least $40 in the short term. This stock runs up fast!!!
FDA clearance
Peer review in Medical Journal
More funding
Everything will be okay
The more shorts the better the squeeze.
The evidence is all that matters; not opinions.
Good luck, and take a chill pill.
If you're holding and can't stomach what you're seeing, turn your computer off, you'll feel a lot better :)
If you like Pfizer, then buy their stock. If you hate INO, sell.
Only people crying about the price are short term traders. Longs see the evidence. All these downgrades don't erase the facts. INO will have a working vaccine and the current price is an illusion.
$8 billion buys the whole 159 mil OS at $50 with proven vaccine, and with proven vaccine, $50 is undervalued.
Rant on, then move on.
Agree. The institutions are trying to teach Robinhood millennials a lesson. LOL
Yeah, but the point is Robinhood shouldn't be sharing client data. Does TD do that? Does Schwab do that? Does E-trade share client data? Since all broker commissions are pretty much $0 thus bad business for Robinhood's bottom line I guess Robinhood has become so desperate that they're releasing client data.
Retail is treated like chit.
You must have lost a ton of money here cause you can't stop blaming the company. Blame someone else. Blame Andrew Left. Blame Clay Trader. Blame Piper Sandler, Blame Maxim, Blame Roth Capital.
INO is doing their job. LOL
All the articles as of late have been about what millennials are buying on Robinhood and how much money that have been making, thus causing institutions to "chase". These same institutions are trying to get their revenge by shorting and negative press/downgrades.
Citron is a prime example by saying "INO has become a chew toy for Robinhood traders" (paraphrasing).